NIF3L1 BP1 Inhibitors
Chemical inhibitors of NIF3L1 BP1 can target various stages of the cell cycle, where the protein is involved in cellular regulation. Alsterpaullone, Roscovitine, and Olomoucine are three such inhibitors that primarily focus on cyclin-dependent kinases (CDKs), essential regulators of cell cycle progression. By inhibiting CDKs, these chemicals can disrupt the normal cycle of cell division and growth. Specifically, Alsterpaullone's action on CDKs can lead to a decrease in transcriptional activities, indirectly impacting the functional concentration of NIF3L1 BP1. Similarly, Roscovitine's selective inhibition of CDKs can decrease phosphorylation of substrates involved in the cell cycle, which can also indirectly inhibit NIF3L1 BP1's function due to altered cell cycle dynamics. Olomoucine's ability to arrest the cell cycle further highlights the potential for indirect inhibition of NIF3L1 BP1 through interference with protein turnover and synthesis that are typically regulated during specific cell cycle phases.
Continuing with this theme, Purvalanol A, Indirubin-3'-monoxime, and Flavopiridol also inhibit CDKs, impacting cell cycle progression and, consequently, the function of NIF3L1 BP1. Purvalanol A's alteration of cell cycle progression restrains the environment where NIF3L1 BP1 functions, thereby inhibiting it. Indirubin-3'-monoxime's capacity to block CDKs further substantiates the concept of influencing cell cycle regulation mechanisms, which in turn can inhibit the activity of NIF3L1 BP1. Flavopiridol, with its synthetic flavone-based structure, attacks various CDKs, resulting in the reduction of protein phosphorylation processes that are intrinsically linked to cell cycle control and indirectly to NIF3L1 BP1 function. AT7519, Dinaciclib, and AZD5438 serve similar functions by suppressing cell cycle progression, thereby influencing the cellular activities that involve NIF3L1 BP1. SNS-032, PHA-793887, and RGB-286638 round out the list by targeting multiple CDKs, which can lead to a comprehensive inhibition of cell cycle progression and indirectly inhibit NIF3L1 BP1 by altering the biogenesis and turnover of proteins involved in cell cycle regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), which are essential for the cell cycle. By inhibiting CDKs, alsterpaullone can lead to a decrease in the transcription of various proteins, indirectly affecting the cellular concentration and function of NIF3L1 BP1 as it is involved in the cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a purine derivative that selectively inhibits CDKs. Through the inhibition of these kinases, roscovitine lowers the phosphorylation of various substrates involved in the cell cycle, potentially leading to a lower functional activity of NIF3L1 BP1 due to altered cell cycle dynamics. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a CDK inhibitor that can arrest the cell cycle. By doing so, it can indirectly inhibit the function of NIF3L1 BP1 by affecting the protein turnover and synthesis processes that are cell cycle-dependent. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is another CDK inhibitor, which could indirectly inhibit NIF3L1 BP1 by altering the cell cycle progression, thereby affecting the cellular environment in which NIF3L1 BP1 operates. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is known to inhibit CDKs and is used to study cell cycle regulation. By inhibiting CDKs, the chemical can indirectly inhibit the function of NIF3L1 BP1 by disrupting normal cell cycle control mechanisms. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a synthetic flavone that inhibits various CDKs. By inhibiting these kinases, flavopiridol can reduce the phosphorylation of proteins involved in the cell cycle, potentially leading to an inhibition of NIF3L1 BP1 function. | ||||||
AT-7519 Hydrochloride | 902135-91-5 | sc-482715 | 5 mg | $125.00 | ||
AT7519 is a multi-CDK inhibitor that can suppress cell cycle progression. By doing this, it can indirectly inhibit the function of NIF3L1 BP1, which is involved in processes related to cell cycle and growth. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor. It can indirectly inhibit NIF3L1 BP1 by halting cell cycle progression and thus affecting the cellular activities that NIF3L1 BP1 is involved in. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is an inhibitor of CDK1, CDK2, and CDK9, which can lead to an indirect inhibition of NIF3L1 BP1 by altering the cell cycle and hence the cellular context of its function. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor of CDK2, CDK7, and CDK9. The inhibition of these kinases can indirectly inhibit NIF3L1 BP1 by affecting transcription regulation and cell cycle control. | ||||||